MESALO MEaSure ALOpecia
Research type
Research Study
Full title
Development of a MEaSure of the severity and impact of chemotherapy-induced ALOpecia. 'MESALO'
IRAS ID
148559
Contact name
Annie Young
Contact email
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Chemotherapy-induced alopecia is repeatedly ranked by cancer patients as one of the five most feared and stigmatised side-effects of treatment. Thus, alopecia often has a negative influence on patient-reported outcomes (PROs), including the patient’s perception of the severity of alopecia and its impact on health-related quality of life (HRQoL). Therefore, it is important to be able to assess alopecia and its impact in a common, valid and reliable manner, both in clinical trials of new chemotherapeutic agents, and in clinical practice.
The aim of this project is to develop an internationally validated measure of chemotherapy-induced alopecia of the scalp.
Part A: HairQoL: Quality of life
Part B: Severity of alopecia (name of the measure to be decided upon)A number of investigators from different countries, with an active research interest in alopecia and scalp cooling, will take part in this project, thus ensuring an optimal cross-cultural setting for the validation process. The participating countries are: Australia, France, Germany, the Netherlands, the United Kingdom and Venezuela.
REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
14/WM/1234
Date of REC Opinion
4 Feb 2015
REC opinion
Further Information Favourable Opinion